Novel Targeted Therapies in Ovarian Cancer
Laurie Elit* and Hal Hirte
Departments of Obstetrics and Gynecology and Oncology, McMaster University, Hamilton, Ontario, Canada
- *Corresponding Author:
- Elit L
Departments of Obstetrics and Gynecology and Oncology
McMaster University, 699 Concession Street
Hamilton, Ontario, Canada L8V 5C2
Tel: 905 389-5688
Fax: 905 575-6343
E-mail: [email protected]
Received date: August 01, 2014; Accepted date: September 17, 2014; Published date: September 19, 2014
Citation: Elit L, Hirte H (2014) Novel Targeted Therapies in Ovarian Cancer. J Cancer Sci Ther 6:350-362. doi:10.4172/1948-5956.1000293
Copyright: © 2014 Elit L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Traditional management of women with advanced ovarian cancer with surgery and chemotherapy provides limited duration of survival. Targeting specific pathways in angiogenesis or DNA repair may provide therapeutic benefit.
Results: In this manuscript, we review the use of various compounds including antibodies that target specific growth factors receptors or ligands for receptors as well as small molecule compounds that inhibit tyrosine kinase activities or regulate the DNA repair mechanism in the management of women with ovarian, fallopian tube and primary peritoneal cancers. Randomized clinical trials have shown a PFS benefit in the use of bevacizumab in the adjuvant setting and at disease recurrence. Randomized clinical trials are currently ongoing with several PARP inhibitors in the maintenance setting post-chemotherapy and in the recurrent disease setting.
Conclusion: In particular, bevacizumab an antibody to VEGF-A and the PARP inhibitors show promise in extending overall survival from this disease. Use of these agents especially in a maintenance strategy is promising